Evidence map›Paper›PMID 42144598›Full record

ArticleJournal of nanobiotechnology2026

Combining receptor engineering and intracellular gelation for cell-based antiviral therapy against coxsackievirus B3.

Tonggong Liu, Wenjuan Liu, Ziyuan Peng, Jie Wen, Shengjie Wu, Xiaona Zhao, Jingzhe Wang, Dayong Gu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tonggong Liu *College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Wenjuan Liu *Department of Laboratory Medicine, Shenzhen Key Laboratory of Medical Laboratory and Molecular Diagnostics, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Ziyuan Peng *Department of Laboratory Medicine, Shenzhen Key Laboratory of Medical Laboratory and Molecular Diagnostics, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Jie WenDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Medical Laboratory and Molecular Diagnostics, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Shengjie WuDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Medical Laboratory and Molecular Diagnostics, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Xiaona ZhaoDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Medical Laboratory and Molecular Diagnostics, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China.
Jingzhe WangDepartment of Laboratory Medicine, Shenzhen Key Laboratory of Medical Laboratory and Molecular Diagnostics, Shenzhen Second People's Hospital, Medical Innovation Technology Transformation Center of Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China. wangjz0202@163.com.
Dayong GuCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China. wanhood@email.szu.edu.cn.

Funding

Clinical Research Special Project of the Medical and Health Technology Development Research Center of the National Health Commission WKZX2024DN0181Excellent Science and Technology Innovation Talent Training Program (Doctoral Basic Research Start-up） RCBS20231211090651091Guangdong Basic and Applied Basic Research Foundation 2023A1515220050Guangdong Science and Technology Foundation 2023B0101200003, 2023B110008，2022B1111020001, 2021A1515220084, 2020JD076Innovation Project of Guangxi Graduate Education JGY2023168Medical-Engineering Interdisciplinary Research Foundation of Shenzhen University 2023YG009National Health Commission Hospital Management Research Institute Project JCWJ2024ZD01, JYHRXZ2025B49National Key Research and Development Program of China 2022YFC2302700National Natural Science Foundation of China 8250083176Shenzhen High-level HospitalConstructionFund 2024WQJJ01Shenzhen Portion of Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone HTHZQSWS- KCCYB-2023060Shenzhen Science and Technology Foundation KJZD20230923115359001, JSGG20220301090003004, ZDSYS20210623092001003
6 · The paper itself

Abstract

Viral myocarditis (VMC), caused by pathogens such as coxsackievirus B3 (CVB3), leads to severe cardiac injury and currently lacks specific therapeutic options. Here, we report a biomimetic antiviral strategy based on receptor engineering and intracellular gelation. By combining genetic and protein engineering, we generated a high-affinity Coxsackievirus and adenovirus receptor mutant (Mut-1_CAR) that markedly enhances the binding of host cardiomyocytes to CVB3. Using photochemical crosslinking, these engineered cells were converted into structurally stable, function-retaining gelated cells (PMs). PMs efficiently adsorb and neutralize virus particles, significantly reducing CVB3 plaque formation in vitro. In a murine model of viral myocarditis, PMs demonstrated excellent in vivo safety and biocompatibility while effectively lowering viral load and mitigating myocardial injury. This study establishes a "receptor enhancement + function fixation" approach for non-immune-dependent viral neutralization, providing a conceptual and technical foundation for the development of novel cell-based biomimetic antiviral therapies.

Indexed as

Antiviral AgentsCoxsackie and Adenovirus Receptor-Like Membrane ProteinCoxsackievirus InfectionsEnterovirus B, HumanReceptors, VirusAnimalsGelsHumansMiceMyocarditisMyocytes, CardiacProtein EngineeringAntiviral AgentsCoxsackie and Adenovirus Receptor-Like Membrane ProteinGelsReceptors, VirusCoxsackievirus B3Gelated cellsHigh-affinity CAR mutantReceptor engineering

Identifiers

PMID42144598
PMCPMC13352930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.